Oxyresveratrol Enhances the Anti-Cancer Effect of Cisplatin against Epithelial Ovarian Cancer Cells through Suppressing the Activation of Protein Kinase B (AKT)
Biomolecules · 2024
DOI: 10.3390/biom14091140 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2024. Verfasst von Phatarawat Thaklaewphan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Cisplatin, Carcinoma, Ovarian Epithelial, Ovarian Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Thailand Science Research and Innovation, Fundamental Fund 2024, Chiang Mai University, Faculty of Medicine, Chiang Mai University.
Abstract (Originalsprache)
Epithelial ovarian carcinoma poses a significant challenge due to its resistance to chemotherapy and propensity for metastasis, thereby reducing the effectiveness of conventional treatments. Hence, the identification of novel compounds capable of augmenting the anti-cancer efficacy of platinum-based chemotherapy is imperative. Oxyresveratrol (OXY), a derivative of resveratrol, has been demonstrated to possess antiproliferative and apoptosis-inducing effects across various cancer cell lines. Notably, OXY appears to exert its effects by inhibiting the PI3K/AKT/mTOR signaling pathway. However, the synergistic potential of OXY in combination with cisplatin against epithelial ovarian cancer has not yet been elucidated. The current study investigated the synergistic effects of OXY and cisplatin on the ovarian cancer cell lines SKOV3 and TOV21G. We found that OXY significantly enhanced cisplatin’s ability to reduce cell viability, induce apoptosis, induce cell cycle arrest, and increase the proportion of cells in the sub-G1 phase. Furthermore, OXY treatment alone dose-dependently inhibited the production of anti-apoptotic proteins including Mcl-1, Bcl-xL, and XIAP under EGF activation. Mechanistically, OXY suppressed the PI3K/AKT/mTOR signaling pathway by reducing phosphorylated AKT, while having no discernible effect on the MAPK pathway. These findings highlight OXY’s potential to enhance ovarian cancer cell sensitivity to chemotherapy, suggesting its development as a pharmaceutical adjunct for clinical use in combination therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.
- Graduate School, Chiang Mai University, Chiang Mai 50200, Thailand.
- Lanna Rice Research Center, Chiang Mai University, Chiang Mai 50200, Thailand.
ORCID-Profile: Phatarawat Thaklaewphan, Nitwara Wikan, Saranyapin Potikanond, Wutigri Nimlamool
Förderung
- Thailand Science Research and Innovation
- Fundamental Fund 2024, Chiang Mai University
- Faculty of Medicine, Chiang Mai University
Zitieren
APA
Thaklaewphan, P., Wikan, N., Potikanond, S., & Nimlamool, W. (2024). Oxyresveratrol Enhances the Anti-Cancer Effect of Cisplatin against Epithelial Ovarian Cancer Cells through Suppressing the Activation of Protein Kinase B (AKT). Biomolecules. https://doi.org/10.3390/biom14091140
Vancouver
Thaklaewphan P, Wikan N, Potikanond S, Nimlamool W. Oxyresveratrol Enhances the Anti-Cancer Effect of Cisplatin against Epithelial Ovarian Cancer Cells through Suppressing the Activation of Protein Kinase B (AKT). Biomolecules. 2024. doi:10.3390/biom14091140
BibTeX
@article{Thaklaewphan2024,
author = {Thaklaewphan, Phatarawat and Wikan, Nitwara and Potikanond, Saranyapin and Nimlamool, Wutigri},
title = {Oxyresveratrol Enhances the Anti-Cancer Effect of Cisplatin against Epithelial Ovarian Cancer Cells through Suppressing the Activation of Protein Kinase B (AKT)},
journal = {Biomolecules},
year = {2024},
doi = {10.3390/biom14091140}
}
EUVIMED